keyword
MENU ▼
Read by QxMD icon Read
search

ttfields

keyword
https://www.readbyqxmd.com/read/29644485/acceptance-and-compliance-of-ttfields-treatment-among-high-grade-glioma-patients
#1
Julia Onken, Franziska Staub-Bartelt, Peter Vajkoczy, Martin Misch
BACKGROUND: Tumor treating fields (TTFields) significantly prolong both progression-free and overall survival in patients with newly diagnosed glioblastoma (GBM). TTFields are delivered to the brain tumor via skin transducer arrays and should be applied for a minimum of 18 h per day (≥ 75% compliance). This may cause limited acceptance by patients because of obstacles in daily routine. So far, there are limited data on factors influencing therapy acceptance and compliance. METHODS: In this retrospective study, fourty-one patients with primary GBM or recurrent high grade glioma (rHGG) have been treated with TTFields in our department...
April 11, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29594036/dosimetric-impact-of-a-tumor-treating-fields-device-for-glioblastoma-patients-undergoing-simultaneous-radiation-therapy
#2
Taoran Li, Gaurav Shukla, Cheng Peng, Virginia Lockamy, Haisong Liu, Wenyin Shi
Purpose: A recent randomized phase III clinical trial in patients with glioblastoma demonstrated the efficacy of tumor treating fields (TTFields), in which alternating electric fields are applied via transducer arrays to a patient's scalp. This treatment, when added to standard of care therapy, was shown to increase overall survival from 16 to 20.9 months. These results have generated significant interest in incorporating the use of TTFields during postoperative concurrent chemoradiation...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29564490/use-of-fet-pet-in-glioblastoma-patients-undergoing-neurooncological-treatment-including-tumour-treating-fields-initial-experience
#3
Garry Ceccon, Lazaros Lazaridis, Gabriele Stoffels, Marion Rapp, Manuel Weber, Tobias Blau, Phillip Lohmann, Sied Kebir, Ken Herrmann, Gereon R Fink, Karl-Josef Langen, Martin Glas, Norbert Galldiks
PURPOSE: We present our first clinical experience with O-(2-18 F-fluoroethyl)-L-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes. METHODS: We retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33-72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes...
March 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29471879/dosimetric-impact-of-tumor-treating-field-ttfield-transducer-arrays-onto-treatment-plans-for-glioblastomas-a-planning-study
#4
Christoph Straube, Markus Oechsner, Severin Kampfer, Sophia Scharl, Friederike Schmidt-Graf, Jan J Wilkens, Stephanie E Combs
BACKGROUND: Tumor-Treating Fields (TTFields) are a novel treatment strategy for glioblastoma (GBM) that is approved for the use concomitantly to adjuvant chemotherapy. Preclinical data suggest a synergistic interaction of TTFields and radiotherapy (RT). However, the dosimetric uncertainties caused by the highly dense arrays have led to caution of applying the TTF setup during RT. METHODS: In a RW3 slab phantom we compared the MV- and kV-CT based planned dose with the measured dose...
February 23, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29392280/influence-of-treatment-with-tumor-treating-fields-on-health-related-quality-of-life-of-patients-with-newly-diagnosed-glioblastoma-a-secondary-analysis-of-a-randomized-clinical-trial
#5
Martin J B Taphoorn, Linda Dirven, Andrew A Kanner, Gitit Lavy-Shahaf, Uri Weinberg, Sophie Taillibert, Steven A Toms, Jerome Honnorat, Thomas C Chen, Jan Sroubek, Carlos David, Ahmed Idbaih, Jacob C Easaw, Chae-Yong Kim, Jordi Bruna, Andreas F Hottinger, Yvonne Kew, Patrick Roth, Rajiv Desai, John L Villano, Eilon D Kirson, Zvi Ram, Roger Stupp
Importance: Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients' health-related quality of life (HRQoL). Objective: To examine the association of TTFields therapy with progression-free survival and HRQoL among patients with glioblastoma. Design, Setting, and Participants: This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy...
February 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29335650/cns-cancer-ttfields-improve-survival
#6
David Killock
No abstract text is available yet for this article.
March 2018: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/29284495/tumor-treating-fields-ttfields-delay-dna-damage-repair-following-radiation-treatment-of-glioma-cells
#7
Moshe Giladi, Mijal Munster, Rosa S Schneiderman, Tali Voloshin, Yaara Porat, Roni Blat, Katarzyna Zielinska-Chomej, Petra Hååg, Ze'ev Bomzon, Eilon D Kirson, Uri Weinberg, Kristina Viktorsson, Rolf Lewensohn, Yoram Palti
BACKGROUND: Tumor Treating Fields (TTFields) are an anti-neoplastic treatment modality delivered via application of alternating electric fields using insulated transducer arrays placed directly on the skin in the region surrounding the tumor. A Phase 3 clinical trial has demonstrated the effectiveness of continuous TTFields application in patients with glioblastoma during maintenance treatment with Temozolomide. The goal of this study was to evaluate the efficacy of combining TTFields with radiation treatment (RT) in glioma cells...
December 29, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29261637/amino-acid-pet-imaging-of-the-early-metabolic-response-during-tumor-treating-fields-ttfields-therapy-in-recurrent-glioblastoma
#8
Edit Bosnyák, Geoffrey R Barger, Sharon K Michelhaugh, Natasha L Robinette, Alit Amit-Yousif, Sandeep Mittal, Csaba Juhász
Tumor-treating fields (TTFields) therapy is a relatively new treatment approach for malignant gliomas. We evaluated if amino acid PET can detect an objective metabolic response to TTFields therapy in recurrent glioblastomas. PET scanning with alpha[C-11]-methyl-L-tryptophan (AMT) before and 2 to 3 months after the start of TTFields treatment showed an interval decrease of tryptophan uptake in the whole tumor (2 patients) or in a portion of the tumor (1 patient). These data demonstrate that TTFields therapy can induce an early metabolic response in recurrent glioblastoma, and this treatment response can be detected by amino acid PET...
March 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29260225/effect-of-tumor-treating-fields-plus-maintenance-temozolomide-vs-maintenance-temozolomide-alone-on-survival-in-patients-with-glioblastoma-a-randomized-clinical-trial
#9
RANDOMIZED CONTROLLED TRIAL
(no author information available yet)
Importance: Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric fields to the tumor. Objective: To investigate whether TTFields improves progression-free and overall survival of patients with glioblastoma, a fatal disease that commonly recurs at the initial tumor site or in the central nervous system. Design, Setting, and Participants: In this randomized, open-label trial, 695 patients with glioblastoma whose tumor was resected or biopsied and had completed concomitant radiochemotherapy (median time from diagnosis to randomization, 3...
December 19, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29023236/end-to-end-workflow-for-finite-element-analysis-of-tumor-treating-fields-in-glioblastomas
#10
Joshua J Timmons, Edwin Lok, Pyay San, Kevin Bui, Eric T Wong
Tumor Treating Fields (TTFields) therapy is an approved modality of treatment for glioblastoma. Patient anatomy-based finite element analysis (FEA) has the potential to reveal not only how these fields affect tumor control but also how to improve efficacy. While the automated tools for segmentation speed up the generation of FEA models, multi-step manual corrections are required, including removal of disconnected voxels, incorporation of unsegmented structures and the addition of 36 electrodes plus gel layers matching the TTFields transducers...
October 12, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28832384/the-evolving-role-of-tumor-treating-fields-in-managing-glioblastoma-guide-for-oncologists
#11
Stuart H Burri, Vinai Gondi, Paul D Brown, Minesh P Mehta
Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM...
August 24, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28765323/tumor-treating-fields-a-fourth-modality-in-cancer-treatment
#12
REVIEW
Elijah J Mun, Hani M Babiker, Uri Weinberg, Eilon D Kirson, Daniel D Von Hoff
Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response...
January 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28681243/synergistic-inhibition-of-glioma-cell-proliferation-by-withaferin-a-and-tumor-treating-fields
#13
Edwin Chang, Christoph Pohling, Nooshin Beygui, Chirag B Patel, Jarrett Rosenberg, Dong Ho Ha, Sanjiv S Gambhir
Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer. Standard therapies are non-specific and often of limited effectiveness; thus, efforts are underway to uncover novel, unorthodox therapies against GBM. In previous studies, we investigated Withaferin A, a steroidal lactone from Ayurvedic medicine that inhibits proliferation in cancers including GBM. Another novel approach, tumor treating fields (TTFields), is thought to disrupt mitotic spindle formation and stymie proliferation of actively dividing cells...
September 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28604803/impact-of-tumor-position-conductivity-distribution-and-tissue-homogeneity-on-the-distribution-of-tumor-treating-fields-in-a-human-brain-a-computer-modeling-study
#14
Anders Rosendal Korshoej, Frederik Lundgaard Hansen, Axel Thielscher, Gorm Burckhardt von Oettingen, Jens Christian Hedemann Sørensen
BACKGROUND: Tumor treating fields (TTFields) are increasingly used in the treatment of glioblastoma. TTFields inhibit cancer growth through induction of alternating electrical fields. To optimize TTFields efficacy, it is necessary to understand the factors determining the strength and distribution of TTFields. In this study, we provide simple guiding principles for clinicians to assess the distribution and the local efficacy of TTFields in various clinical scenarios. METHODS: We calculated the TTFields distribution using finite element methods applied to a realistic head model...
2017: PloS One
https://www.readbyqxmd.com/read/28544575/analysis-of-physical-characteristics-of-tumor-treating-fields-for-human-glioblastoma
#15
Edwin Lok, Pyay San, Van Hua, Melissa Phung, Eric T Wong
Tumor Treating Fields (TTFields) therapy is an approved treatment that has known clinical efficacy against recurrent and newly diagnosed glioblastoma. However, the distribution of the electric fields and the corresponding pattern of energy deposition in the brain are poorly understood. To evaluate the physical parameters that may influence TTFields, postacquisition MP-RAGE, T1 and T2 MRI sequences from a responder with a right parietal glioblastoma were anatomically segmented and then solved using finite-element method to determine the distribution of the electric fields and rate of energy deposition at the gross tumor volume (GTV) and other intracranial structures...
June 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28524900/tumor-treating-fields-nursing-implications-for-an-emerging-technology%C3%A2
#16
Alice Chang
Tumor-treating fields (TTFields) are a new technology used for cancer treatment consisting of battery-powered, insulated electromagnetic transducers that are placed on the scalp. This wearable, adhesive device is a certified physician-prescribed therapy for patients with glioblastoma multiforme, a type of primary brain cancer. TTFields are being used concomitantly with temozolomide (Temodar®) in patients with newly diagnosed glioblastoma and as a monotherapy in patients with recurrent glioblastoma after radiation therapy and chemotherapy...
June 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/28518093/determining-the-optimal-inhibitory-frequency-for-cancerous-cells-using-tumor-treating-fields-ttfields
#17
Yaara Porat, Moshe Giladi, Rosa S Schneiderman, Roni Blat, Anna Shteingauz, Einav Zeevi, Mijal Munster, Tali Voloshin, Noa Kaynan, Orna Tal, Eilon D Kirson, Uri Weinberg, Yoram Palti
Tumor Treating Fields (TTFields) are an effective treatment modality delivered via the continuous, noninvasive application of low-intensity (1-3 V/cm), alternating electric fields in the frequency range of several hundred kHz. The study of TTFields in tissue culture is carried out using the TTFields in vitro application system, which allows for the application of electric fields of varying frequencies and intensities to ceramic Petri dishes with a high dielectric constant (Ɛ > 5,000). Cancerous cell lines plated on coverslips at the bottom of the ceramic Petri dishes are subjected to TTFields delivered in two orthogonal directions at various frequencies to facilitate treatment outcome tests, such as cell counts and clonogenic assays...
May 4, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28425987/biological-activity-of-tumor-treating-fields-in-preclinical-glioma-models
#18
Manuela Silginer, Michael Weller, Roger Stupp, Patrick Roth
Glioblastoma is the most common and aggressive form of intrinsic brain tumor with a very poor prognosis. Thus, novel therapeutic approaches are urgently needed. Tumor-treating fields (TTFields) may represent such a novel treatment option. The aim of this study was to investigate the effects of TTFields on glioma cells, as well as the functional characterization of the underlying mechanisms. Here, we assessed the anti-glioma activity of TTFields in several preclinical models. Applying TTFields resulted in the induction of cell death in a frequency- and intensity-dependent manner in long-term glioma cell lines, as well as glioma-initiating cells...
April 20, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28399638/tumor-treating-fields-plus-chemotherapy-versus-chemotherapy-alone-for-glioblastoma-at-first-recurrence-a-post-hoc-analysis-of-the-ef-14-trial
#19
Santosh Kesari, Zvi Ram
BACKGROUND: This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence. METHODS: Patients on TTFields plus temozolomide continued TTFields plus second-line chemotherapy after first recurrence. Some patients on temozolomide alone crossed over after approval of TTFields for recurrent GBM...
April 12, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28358361/tumor-treating-fields-elicit-a-conditional-vulnerability-to-ionizing-radiation-via-the-downregulation-of-brca1-signaling-and-reduced-dna-double-strand-break-repair-capacity-in-non-small-cell-lung-cancer-cell-lines
#20
Narasimha Kumar Karanam, Kalayarasan Srinivasan, Lianghao Ding, Brock Sishc, Debabrata Saha, Michael D Story
The use of tumor-treating fields (TTFields) has revolutionized the treatment of recurrent and newly diagnosed glioblastoma (GBM). TTFields are low-intensity, intermediate frequency, alternating electric fields that are applied to tumor regions and cells using non-invasive arrays. The predominant mechanism by which TTFields are thought to kill tumor cells is the disruption of mitosis. Using five non-small cell lung cancer (NSCLC) cell lines we found that there is a variable response in cell proliferation and cell killing between these NSCLC cell lines that was independent of p53 status...
March 30, 2017: Cell Death & Disease
keyword
keyword
110947
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"